OHRP News Alert Ohr Pharmaceutical Inc (OHRP) 7.45 11/13/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 6:14 PM

Ohr Pharmaceutical Inc (OHRP) 7.45 $OHRP

Ohr Pharmaceutical to Host Key Opinion Leader Meeting and Webcast on October 31 in New York City
GlobeNewswire - Mon Oct 27, 7:01AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will host a Key Opinion Leader analyst breakfast on Friday, October 31, 2014 from 8:00 am-9:30 am Eastern Time in New York City. The meeting will feature discussions by two retinal disease experts, K. Bailey Freund, M.D., and Ohr's Chief Medical Officer, Jason S. Slakter, MD.
OHRP: 7.45 (+0.18)

Ohr Pharmaceutical Announces New Positive Anatomic and Visual Acuity Data on OHR-102 (Squalamine Eye Drops) IMPACT Study Presented at the 2014 American Academy of Ophthalmology Scientific Meeting
GlobeNewswire - Mon Oct 20, 6:15AM CDT
Reduction of Subretinal Hyperreflective Material (SHRM) Induced by OHR-102 Correlates With Improved Vision Outcomes
OHRP: 7.45 (+0.18)

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
at The Street - Fri Oct 17, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AVNR: 13.14 (-0.04), OHRP: 7.45 (+0.18), MNKD: 6.18 (+0.10), ARNA: 4.61 (-0.09)

Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 6:00PM CDT
Ohr Pharmaceutical, Inc.'s (OHRP) OHR-102 will enter phase III studies with the primary endpoint being improvement in visual acuity at 9 months.
AMPE: 3.38 (+0.11), OHRP: 7.45 (+0.18), REGN: 402.63 (+1.52)

Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD
GlobeNewswire - Tue Oct 14, 6:15AM CDT
Primary Endpoint for Approval to be Based on Visual Acuity Improvements at 9 Months
OHRP: 7.45 (+0.18)

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the 2014 American Academy of Ophthalmology Scientific Meeting
GlobeNewswire - Tue Oct 07, 7:02AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that additional positive anatomic and visual acuity data from the IMPACT study, a phase II clinical trial evaluating Squalamine eye drops (OHR-102) for the treatment of the wet form of age-related macular degeneration (wet AMD), will be presented in two separate podium sessions at the 2014 American Academy of Ophthalmology (AAO) Annual Scientific Meeting, being held in Chicago, Illinois, from October 17-21, 2014.
OHRP: 7.45 (+0.18)

Retinal Vein Occlusion - Pipeline Review, H2 2014 - 8 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3bmznr/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - NicOx S.A. - ThromboGenics NV - Ohr Pharmaceutical Inc. - Kala Pharmaceuticals, Inc. - Mabion SA Drug Profiles - fluocinolone acetonide - squalamine lactate - beclomethasone dipropionate - loteprednol etabonate - ranibizumab - ocriplasmin (recombinant) - NCX-434 - NCX-422 - AVA-101 - ranibizumab biosimilar For more information visit http://www.researchandmarkets.com/research/3b...tinal_vein
AGN: 196.21 (-0.30), OHRP: 7.45 (+0.18)

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the Retina Society 47th Annual Scientific Meeting
GlobeNewswire - Tue Sep 09, 8:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that data from the IMPACT study, a phase II clinical trial evaluating Squalamine eye drops (OHR-102) for the treatment of the wet form of age-related macular degeneration (wet AMD), will be presented in two separate sessions at the Retina Society 47 Annual Scientific Meeting, being held in Philadelphia, Pennsylvania from September 11-14, 2014.
OHRP: 7.45 (+0.18)

Ohr Pharmaceutical Announces Additional Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Wet-AMD; The IMPACT Study
GlobeNewswire - Wed Aug 13, 7:30AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced additional interim data from the Phase II study evaluating Squalamine Eye Drops (OHR-102) for the treatment of the wet form of age-related macular degeneration ("wet-AMD"

. The data demonstrated a visual acuity and anatomical benefit for the group of patients receiving the combination of OHR-102 and Lucentis PRN ("OHR-102 arm"

versus placebo eye drops plus Lucentis PRN ("Lucentis monotherapy arm"

. Jason Slakter, MD, retina specialist and Chief Medical Officer at Ohr, presented the data on Tuesday, August 12 at the 2014 Annual Meeting of the American Society of Retina Specialists ("ASRS"

.
OHRP: 7.45 (+0.18)

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
GlobeNewswire - Mon Aug 11, 8:59AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced data supporting the use of Squalamine Eye Drops (OHR-102) in the treatment of macular edema secondary to branch (BRVO) or central retinal vein occlusion (CRVO). The data demonstrated that the combination of topical Squalamine eye drops and intravitreal Lucentis(R) led to a mean gain in visual acuity ("VA"

of 20.3 letters and resolution of the fovial edema in 95% of the patients at week 10. John Wroblewski, MD, retina specialist at Cumberland Valley Retina Consultants, presented the 10 week data on Saturday, August 9 at the 2014 Annual Meeting of the American Society of Retina Specialists.
OHRP: 7.45 (+0.18)

Ohr Pharmaceutical to Present at the 2014 Wedbush Life Sciences Management Access Conference
GlobeNewswire - Fri Aug 08, 7:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Sam Backenroth, Chief Financial Officer, will present a corporate overview and business update at the 2014 Wedbush Life Sciences Management Access Conference, being held at the Le Parker Meridien Hotel in New York City on August 12-13, 2014.
OHRP: 7.45 (+0.18)

Ohr Pharmaceutical Announces Upcoming Squalamine Eye Drop Clinical Data Presentations at the 2014 Annual Meeting of the American Society of Retina Specialists
GlobeNewswire - Thu Aug 07, 8:32AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that data from clinical studies evaluating Squalamine eye drops for the treatment of macular edema secondary to central and branch retinal vein occlusion, and the wet form of age-related macular degeneration (wet AMD), will be presented in two separate sessions at the 2014 Annual Meeting of the American Society of Retina Specialists, being held at the Hilton Bayfront Hotel in San Diego, California.
OHRP: 7.45 (+0.18)

Can the Rally in OHR Pharmaceutical (OHRP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 8:19AM CDT
Can the Rally in OHR Pharmaceutical (OHRP) Shares Continue?
OHRP: 7.45 (+0.18)

4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Aug 01, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
CRMD: 1.40 (-0.28), ACRX: 6.77 (-0.18), THLD: 3.01 (-0.13), OHRP: 7.45 (+0.18)

Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 7:44AM CDT
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares surge nearly 7% on the day.
SGYP: 3.07 (-0.08), BCRX: 10.39 (-0.39), OHRP: 7.45 (+0.18), ANAC: 31.46 (-0.31)

Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox
at The Street - Fri Jul 18, 6:51AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
ACRX: 6.77 (-0.18), XBI: 171.34 (-2.34), OHRP: 7.45 (+0.18), NYMX: 0.49 (-0.09), ENTA: 43.22 (-0.09)

Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:44AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 7% on the day.
SGYP: 3.07 (-0.08), BCRX: 10.39 (-0.39), OHRP: 7.45 (+0.18), GNCA: 8.94 (-0.06)

Strength Seen in La Jolla Pharmaceutical Co. (LJPC): Stock Shoots 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 7:44AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge 19% on the day.
SGYP: 3.07 (-0.08), BCRX: 10.39 (-0.39), LJPC: 11.06 (-2.08), OHRP: 7.45 (+0.18)

Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock up 8.37% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:44AM CDT
Aerie Pharmaceuticals, Inc. (AERI) was a big mover last session, as the company saw its shares rise over 8% on the day.
SGYP: 3.07 (-0.08), BCRX: 10.39 (-0.39), AERI: 24.37 (-0.68), OHRP: 7.45 (+0.18)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...